What CMS says about PT/INR self-testing
In a 2001 Decision Memoradum, Medicare cites clinical evidence supporting Coumadin self-testing on a weekly basis. The Centers for Medicare and Medicaid (CMS) concluded:
The studies reviewed demonstrated home PT/INR monitoring significantly improves time in therapeutic range for select groups of patients, compared to testing done in physician offices or anticoagulation clinics.
Increased time in therapeutic range leads to improved clinical outcomes, with reductions in thromboembolic and hemorrhagic events.
In order to achieve time in therapeutic range of 90%, a patient most likely needs to be tested once a week.
(CMS Decision Memorandum #CAG-00087N September 18, 2001)
Click here to read and/or download a copy of the CPT codes and additional information from CMS.